Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q2- Text added to 2019 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
New words:
AB, ACME, apremilast, argument, attention, bipartisan, BMS, CANDOR, Celgene, comprised, contention, country, curiae, daratumumab, DARZALEX, discover, disposition, disturbing, divert, divestiture, duration, endpoint, footprint, formatted, fraud, FTC, heard, history, immunogenicity, infarction, intervenor, Irrevocable, light, lymphoma, Maine, margin, merger, myocardial, nonbiologic, nonkey, Nuevolution, oral, Otezla, oversaw, overturning, Page, payor, personnel, petitioner, platform, prespecified, proceeding, psoriatic, reissued, rejecting, Rituxan, rituximab, role, Senate, shorter, showing, speed, Squibb, standing, stroke, Technical, timeframe, unanticipated, unopposed, unsettled, upholding, Vermont, waived, week
Valuein 2019 Q2 filing- Value in 2019 Q3 filing
Original filings
Filing view